Matthew S. Yong

Matthew S. Yong

Auto-generated profile, based on publicly available information

Matthew S. Yong

Department of Cardiothoracic Surgery, The Alfred Hospital, Melbourne, Australia

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Seminars in Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDF file
PNPhillip S. Naimo
Phillip S. Naimo
TFTyson A. Fricke
Tyson A. Fricke
MYMatthew S. Yong
Matthew S. Yong
YDYves D'Udekem
Yves D'Udekem
AKAndrew Kelly
Andrew Kelly
IKIgor E. Konstantinov
Igor E. Konstantinov

1 May 2014 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
MYMatthew S. Yong
Matthew S. Yong
DYDeane Yim
Deane Yim
CBChristian P. Brizard
Christian P. Brizard
TRTerry Robertson
Terry Robertson
ABAndrew Bullock
Andrew Bullock
IKIgor E. Konstantinov
Igor E. Konstantinov

1 June 2011 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
MYMatthew S. Yong
Matthew S. Yong
YDYves D'Udekem
Yves D'Udekem
TRTerry Robertson
Terry Robertson
SHStephen Horton
Stephen Horton
MDMithilesh Dronavalli
Mithilesh Dronavalli
IKIgor E. Konstantinov
Igor E. Konstantinov

20 September 2013 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
OXO. Xie
O. Xie
CBC. P. Brizard
C. P. Brizard
YDY. D'UDekem
Y. D'UDekem
JGJ. C. Galati
J. C. Galati
AKA. Kelly
A. Kelly
IKI. E. Konstantinov
I. E. Konstantinov
We sought to evaluate the surgical outcomes of the repair of complete atrioventricular septal defects (cAVSDs) in our institution in the current era. From 2000 to 2011, 138 patients underwent definitive repair of cAVSD. Repair was performed using a two-patch technique in 92.0% of patients and one-patch technique in 2.2%, and the ventricular septal component was closed directly in 5.8% of patients. Operative mortality was 1.4% (2 of 138). Overall mortality was 5.8% (8 of 138). Follow-up was 96% complete. Freedom from reoperation was 84.3% (95% CI 77.1-91.5%) at 8 years. Age >6 months at repair was associated with higher rates of reoperation (P = 0.001; HR 6.85; 95% CI 2.30-20.44). However, operating at <6 months of age was associated with longer intensive care unit stay (P = 0.019; median 2.7 vs 1.4 days), mechanical ventilation (P = 0.001; median 1.7 vs 0.9 days) and postoperative hospital stay (P = 0.016; median 8 vs 5 days). Moderate or greater left atrioventricular valvular regurgitation (LAVVR) at discharge was a risk factor for reoperation (P < 0.001; HR 10.85; 95% CI 3.75-31.40). Repair of cAVSD carries low mortality, but a moderate reoperation rate. An optimal time for repair of the cAVSD is between 3 and 6 months of age. Repair prior to 3 months of age and the need for cleft closure were associated with a higher degree of LAVVR at discharge. Greater LAVVR at discharge is a risk factor for reoperation regardless of age at initial repair. In the current era, Down's syndrome is not a risk factor for reoperation.

1 April 2013 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
MYMatthew S. Yong
Matthew S. Yong
YDYves D'Udekem
Yves D'Udekem
CBChristian P. Brizard
Christian P. Brizard
TRTerry Robertson
Terry Robertson
CRColin F. Robertson
Colin F. Robertson
IKIgor E. Konstantinov
Igor E. Konstantinov

21 March 2016 in Heart
Verified
Journal Article
Closed access
PDF file
WSWilliam Y Shi
William Y Shi
MYMatthew S Yong
Matthew S Yong
DMDavid C McGiffin
David C McGiffin
PJPankaj Jain
Pankaj Jain
PRPeter N Ruygrok
Peter N Ruygrok
IKIgor E Konstantinov
Igor E Konstantinov
Objective Patients with Fontan physiology may eventually require heart transplantation (HT). We determined the rates and outcomes of HT in a national, population-based multicentre study. Methods From 1990 to 2015, 1369 patients underwent the Fontan procedure as recorded in the Australia and New Zealand Fontan Registry. We identified those who underwent HT and analysed their outcomes. We compared rates of HT between two catchment areas. In area 1 (n=721), patients were referred to the national paediatric HT programme or its associated adult programme. In area 2 (n=648), patients were referred to the national paediatric HT programme or one of the other adult HT programmes. Results Mean follow-up time post-Fontan was 11±8 years. Freedom from Fontan failure was 74%±3.9% at 20 years. HT was performed in 34 patients. Patients living in area 1 were more likely to have HT (4.0%, 29/721 vs 0.8%, 5/648, p<0.001) with a cumulative proportion of 3.4% vs 0.7% at 10 years and 6.8% vs 1.2% at 20 years (p=0.002). Area 1 patients were more likely to undergo HT (hazard ratio 4.7, 95% CI 1.7 to 13.5, p=0.003) on multivariable regression. Post-HT survival at 1, 5 and 10 years was 91%, 78% and 71%, respectively. Compared with other patients with congenital heart disease (n=87), Fontan patients had similar in-hospital outcomes and long-term survival. Conclusions Although HT after the Fontan procedure can be achieved with excellent outcomes, most patients with Fontan failure do not undergo HT. Significant regional differences in rates of HT in Fontan patients exist.